Dark

Check out our Level2View

ACR
ACRES Commercial Realty Corp.
stock NYSE

At Close

Sep 25, 2026 3:59:50 PM EDT

10.53USD-3.923%(-0.43)59,207

0.00Bid 0.00Ask 0.00Spread

Pre-market

0.00USD-100.000%(-10.96)0

After-hours

Sep 24, 2026 4:10:30 PM EDT

10.96USD+0.091%(+0.01)0

OverviewOptionsHistoricalExchangesShortsTrends

ACR Reddit Mentions

Subreddits

Limit Labels Price

We have sentiment values and mention counts going back to 2017. The complete data set is available via the API.

Take me to the API

ACR Specific Mentions

As of Sep 26, 2026 6:05:58 PM EDT (1 min. ago)

Includes all comments and posts. Mentions per user per ticker capped at one per hour.

1 day ago • u/HunterMichael92 • r/ValueInvesting • nktx_posteroral_presentation_november_2026 • Stock Analysis • B

Nkarta, Inc. is preparing to release results from the NTRUST-1/2 Trials related to Myositis and Scleroderma at the ACR Conference, they were awarded a Safety Presentation as well on the efficacy and 0 side-effect therapies they have been dosing patients.

CEO Paul Hastings on Stifel's investor forum questioned multiple aspects of their progress to date and both Hastings and President reinforced their findings and excitement to release not only results but durability of the drug.
Their stock is currently trading at $2.77 below cash value and a healthy pipeline to get past results and into FDA track for approval.
I am long 150,000 shares as of today, and will increase position ahead of the November readout.

$NKTX

1 day ago • u/HunterMichael92 • r/ValueInvesting • nktx_posteroral_presentation_november_2026 • Stock Analysis • B

Nkarta, Inc. is preparing to release results from the NTRUST-1/2 Trials related to Myositis and Scleroderma at the ACR Conference, they were awarded a Safety Presentation as well on the efficacy and 0 side-effect therapies they have been dosing patients.

CEO Paul Hastings on Stifel's investor forum questioned multiple aspects of their progress to date and both Hastings and President reinforced their findings and excitement to release not only results but durability of the drug.
Their stock is currently trading at $2.77 below cash value and a healthy pipeline to get past results and into FDA track for approval.
I am long 150,000 shares as of today, and will increase position ahead of the November readout.

$NKTX

Share